These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38012435)

  • 1. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Loi M; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Iezza M; Baratè C; Scaffidi L; Elena C; Giai V; Scalzulli E; Breccia M; La Nasa G; Caocci G
    Ann Hematol; 2024 Feb; 103(2):427-436. PubMed ID: 38012435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
    Caocci G; Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Sgherza N; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Gugliotta G; Baratè C; Scaffidi L; Elena C; Pirillo F; Scalzulli E; La Nasa G; Foà R; Breccia M
    Hematol Oncol; 2019 Aug; 37(3):296-302. PubMed ID: 30892724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
    Caocci G; Mulas O; Capodanno I; Bonifacio M; Annunziata M; Galimberti S; Luciano L; Tiribelli M; Martino B; Castagnetti F; Binotto G; Pregno P; Stagno F; Abruzzese E; Bocchia M; Gozzini A; Albano F; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; Baratè C; De Gregorio F; Stella R; Gugliotta G; Pirillo F; Trawinska MM; Sicuranza A; Cattaneo D; Attolico I; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
    Ann Hematol; 2021 Aug; 100(8):2005-2014. PubMed ID: 33388860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
    Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
    J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.
    Levy M; Xie L; Wang Y; Neumann F; Srivastava S; Naranjo D; Xu J; Zhang Q; Dalal M
    Cancer Treat Res Commun; 2021; 28():100424. PubMed ID: 34198039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
    Abdelmagid MG; Al-Kali A; Litzow MR; Begna KH; Hogan WJ; Patnaik MS; Hashmi SK; Elliott MA; Alkhateeb H; Karrar OS; Fleti F; Elnayir MH; Rivera CE; Murthy HS; Foran JM; Kharfan-Dabaja MA; Badar T; Viswanatha DS; Reichard KK; Gangat N; Tefferi A
    Blood Cancer J; 2023 Aug; 13(1):122. PubMed ID: 37567878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by the Systematic Coronary Risk Estimation 2 algorithm.
    Szczepanek E; Marczyk B; Chukwu O; Chlopicki S; Sacha T
    Pol Arch Intern Med; 2024 Jun; 134(6):. PubMed ID: 38572907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.
    Caocci G; Mulas O; Bonifacio M; Abruzzese E; Galimberti S; Orlandi EM; Iurlo A; Annunziata M; Luciano L; Castagnetti F; Gozzini A; Stagno F; Binotto G; Pregno P; Albano F; Martino B; Fozza C; Scaffidi L; Trawinska MM; Baratè C; Elena C; Cattaneo D; Scalzulli E; La Nasa G; Foà R; Breccia M
    Int J Cardiol; 2019 Aug; 288():124-127. PubMed ID: 31029498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
    Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
    Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
    Yang J; Surapaneni M; Schiffer CA
    Expert Rev Hematol; 2022 May; 15(5):393-402. PubMed ID: 35544670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
    Tojo A; Kyo T; Yamamoto K; Nakamae H; Takahashi N; Kobayashi Y; Tauchi T; Okamoto S; Miyamura K; Hatake K; Iwasaki H; Matsumura I; Usui N; Naoe T; Tugnait M; Narasimhan NI; Lustgarten S; Farin H; Haluska F; Ohyashiki K
    Int J Hematol; 2017 Sep; 106(3):385-397. PubMed ID: 28444644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
    Pulte ED; Chen H; Price LSL; Gudi R; Li H; Okusanya OO; Ma L; Rodriguez L; Vallejo J; Norsworthy KJ; de Claro RA; Theoret MR; Pazdur R
    Oncologist; 2022 Mar; 27(2):149-157. PubMed ID: 35641211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
    Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.
    Breccia M; Molica M; Zacheo I; Serrao A; Alimena G
    Ann Hematol; 2015 Mar; 94(3):393-7. PubMed ID: 25304102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
    Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
    Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
    Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
    Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia].
    Réa D; Messas E; Mirault T; Nicolini FE
    Bull Cancer; 2022; 109(7-8):862-872. PubMed ID: 35725593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.